Stay updated with breaking news from Applied Clinical Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma - read this article along with other careers information, tips and advice on BioSpace
A procedure that applies pulses of focused ultrasound to the brain is safe and effective for reducing tremors and improving quality of life in people with essential tremor (ET) or Parkinson's...
A new study in the journal Sleep finds that increased evening screen time during the Covid-19 lockdown negatively affects sleep quality.
VANCOUVER, BC, Jan. 19, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that executives of the Company will speak at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe ("CDP Europe"). CDP Europe will be held virtually from January 19-21, 2021. Michael Woudenberg - Vice President, Chemistry, Manufacturing & Controls, Karen Long - Senior...